References
- Brenning G, Ahre A, Nilsson K. Correlation between in vitro and in vivo sensitivity of human leukocyte interferon in patients with multiple myeloma. Scand J Haematol 1985; 35: 543–9
- Ahre A, Björkholm M, Österborg A, et al. High dose of natural alpha interferon (alpha-IFN) in the treatment of multiple myeloma. A pilot study from the Myeloma Group of Central Sweden (MGCS). Eur J Haematol 1988; 41: 123–30
- Cooper M R, Dear K, McIntyre O R, et al. A randomized clinical trial comparing melphalan/prednisone with or without interferon alfa-2b in newly diagnosed patients with multiple myeloma: a Cancer and Leukemia Group B Study. J Clin Oncol 1993; 11: 155–60
- Corrado C, Pavlovsky S, Saslasky J, et al. Randomized trial comparing melphalan/prednisone with or without recombinant alpha 2 interferon (rIFN-2) in multiple myeloma. Proc Am Soc Clin Oncol 1989; 8: 1007
- Kyle R A, Oken M M, Greipp P R, et al. VBMCP/rlFN alfa-2. Induction therapy in multiple myeloma. VBMCP/rlFN alfa-2. Induction therapy in multiple myeloma, HanoverGermany, February, 1990; 46A
- Mandelli F, Avvisati G, Amadori S, et al. Maintenance therapy with recombinant interferon 2b in patients with multiple myeloma responding to conventional induction chemotherapy. N Engl J Med 1990; 322: 1430–4
- Salmon S, Crowley J, Tuscon A, et al. Impact of glucocorticoids (GC) and interferon (IFN) on outcome in multiple myeloma (Abstract 1069). Proceedings of the Am Soc Clin Oncol 1992; 11: 316
- Capnist G, Chisesi T. Does the therapy according to stage improve response and survival in multiple myeloma patients?. Leuk Lymphoma 1991; 3: 409–17